This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Considerations for choosing an appropriate factor product
More frequent dosing may provide higher factor levels1
Depending on patients' needs and lifestyles, continuing with or switching to an SHL factor product may represent an appropriate option.1
Higher factor levels and more frequent peaks may be needed for some patients.1
The importance of peak and trough levels in hemophilia patients is still not clearly understood. However, studies suggest that higher trough levels and greater area under the curve may correlate to fewer bleeds, especially in joints.2
In patients with more sedentary lifestyles longer dose intervals may be acceptable.1
In patients with a less than average half-life prolongation, target joints,* or more on-the move lifestyles, higher and more frequent peak factor levels may be beneficial for sufficient bleed protection.1,3
BeneFIX® offers the flexibility to infuse on-demand or prophylactically based on your patients' needs.4
Soham – a patient currently taking an EHL
Patient profiles are hypothetical and for discussion purposes only.
Currently on an EHL
A 25-year-old patient with severe
hemophilia B. A recent graduate who has just started working for a law firm.
Treatment
Soham is currently on EHL therapy. He has experienced 1 bleeding episode in his ankle and seeks effective control over convenience.
Individual response to EHL therapy may vary. Patients with more active lifestyles, target joints* and below-average half-life prolongation may benefit from higher levels and more frequent peaks.1
Why BeneFIX® may be appropriate for patients like Soham
![]() for prophylaxis, on-demand and surgery5,7,8 |
|||
![]() storage flexibility through room temperature storage (2 - 30 °C).4 Do not freeze4
|
|||
![]() with a predictable PK to support your patient's everyday life10
|
|||
![]() with low inhibitor formation6 |
|||
![]() (250, 500, 1000, 2000, 3000 IU) so you can individualise FIX coverage for your patients4
|
Informed decisions may lead to more favourable outcomes.1,3
To help ensure that patients are actively involved in creating their treatment plan, consider discussing the following points to help determine if an SHL or an EHL is more appropriate:
Lifestyle and activity level
Bleed pattern
Joint health
PK profile
*A target joint is a joint in which 3 or more spontaneous bleeds occurred within a consecutive 6-month period.9
EHL, extended half-life; FIX, factor IX; PK, pharmacokinetics; SHL, standard half-life.
References:
PP-BEN-IND-0025 22/07/22
Patient actively involved in sport
Example
Patient actively involved in sport
BeneFIX® provides dosing options based on individual needs
Learn more
Proven efficacy and protection across dosing regimen
Review efficacy profile
See how BeneFIX® performs in real-life settings.
Review real-world data
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.